

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **ELECTION OF LANGUAGE AND MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS**

Pursuant to Rules 2.07A and 2.07B of the Listing Rules and the Articles, the Company is making arrangements to ascertain the preferences of Shareholders with respect to the election of language and means of receipt of the Company's all future Corporate Communications.

Pursuant to Rules 2.07A and 2.07B of the Listing Rules and the Articles, the Company is making arrangements to ascertain the preferences of Shareholders with respect to election of language and means of receipt of the Company's all future Corporate Communications either: (i) by electronic means through the Company's website at [www.genscript.com](http://www.genscript.com); or (ii) in printed form, in either the English version only, the Chinese version only, or both the English and Chinese versions.

In support of environmental protection and for the purpose of saving printing and mailing costs, the Company recommends the Shareholders to elect the Website Version (as defined below). However, Shareholders shall have the right at any time by giving reasonable notice in writing to the Company c/o the Hong Kong Share Registrar or by email to [genscript.ecom@computershare.com.hk](mailto:genscript.ecom@computershare.com.hk) to change their choice of preferred language and/or means of receipt of the Corporate Communications.

## NEW ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules, the following arrangements will be made by the Company:

1. The Company will send a letter on 21 September 2018 (the “**First Letter**”) together with a reply form with a pre-paid mailing label for posting within Hong Kong only (the “**Reply Form**”), in both English and Chinese, to the Shareholders to enable them to elect any one of the following options for receipt of all future Corporate Communications:
  - (1) to read future Corporate Communications published on the Company’s website at [www.genscript.com](http://www.genscript.com) (“**Website Version**”) in place of receiving printed copies, and receive a printed notification letter of the publication of the Corporate Communications on website by post; or
  - (2) to receive the printed English version of all future Corporate Communications only; or
  - (3) to receive the printed Chinese version of all future Corporate Communications only; or
  - (4) to receive both the printed English and Chinese versions of all future Corporate Communications.

**The First Letter will explain that if the Company does not receive the Reply Form duly completed and signed by the Shareholders or does not receive a response indicating the objection from the Shareholders by 19 October 2018 and until the Shareholders inform the Company c/o Hong Kong Share Registrar by reasonable prior notice in writing or by sending an e-mail to [genscript.ecom@computershare.com.hk](mailto:genscript.ecom@computershare.com.hk), such Shareholders will be deemed to have agreed to access all future Corporate Communications by Website Version in lieu of printed form.**

2. For Shareholders who choose to receive all future Corporate Communications by electronic means through the Company's website at [www.genscript.com](http://www.genscript.com), the Company will send a printed notification letter of the publication of the Corporate Communications on the Company's website to such Shareholders by post. If for any reason, a Shareholder has difficulty in receiving or gaining access to the Website Version of the Corporate Communications, the Company will promptly upon request send the Corporate Communications in printed form to such Shareholder free of charge.
3. For Shareholders who choose to receive the future Corporate Communications in printed form, the Company will send the selected language version(s) of the Corporate Communications to those Shareholders who have made an election unless and until they notify the Company c/o Hong Kong Share Registrar, by reasonable notice to the Hong Kong Share Registrar in writing or email at [genscript.ecom@computershare.com.hk](mailto:genscript.ecom@computershare.com.hk) that they wish to receive the Corporate Communications in the other (or both) language(s), or by electronic means through the Company's website at [www.genscript.com](http://www.genscript.com).
4. As and when each of the printed Corporate Communications is sent out in accordance with the arrangements described in paragraph 3 above, a letter (the "**Second Letter**") together with a change of request form (the "**Change of Request Form**") in both English and Chinese and a pre-paid mailing label (applicable for posting within Hong Kong only) will be attached to the Corporate Communications informing Shareholders that the Corporate Communications prepared in the other language will be available upon request and that Shareholders may at any time by completing and returning the Change of Request Form to the Hong Kong Share Registrar by mail or email at [genscript.ecom@computershare.com.hk](mailto:genscript.ecom@computershare.com.hk) to change their elected means of receipt and/or language of the future Corporate Communications.
5. All future Corporate Communications in both English and Chinese languages and in accessible format will be available on the Company's website at [www.genscript.com](http://www.genscript.com) and the website of Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk).
6. Shareholders can call the Company's Hong Kong Share Registrar's telephone hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding public holidays, in respect of any queries in relation to the Company's new arrangements.
7. The First Letter and the Second Letter will mention that both languages of each Corporate Communication will be available on the Company's website and the dial-up hotline service has been provided as mentioned in the arrangements described in paragraphs 5 and 6 above, respectively.

## DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms should have the following meanings:

“Articles”	the second amended and restated memorandum and articles of association of the Company
“Company”	Genscript Biotech Corporation (金斯瑞生物科技股份有限公司*) (stock code: 1548), a limited company incorporated in the Cayman Islands and the shares of which are listed on the Main Board of the Stock Exchange
“Corporate Communications”	any documents issued or to be issued by the Company for the information or action of holders of any of its securities as defined in Rule 1.01 of the Listing Rules, including but not limited to, the directors’ report and annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report, the interim report and, where applicable, its summary interim report, a notice of meeting, a listing document, a circular and a proxy form
“Hong Kong Share Registrar”	the Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Shareholder(s)”	the holder(s) of the share(s) of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 21 September 2018

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian and Ms. ZHANG Min.*

\* For identification purposes only